Compare ASTL & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTL | ASMB |
|---|---|---|
| Founded | 1902 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.0M | 440.0M |
| IPO Year | N/A | 2010 |
| Metric | ASTL | ASMB |
|---|---|---|
| Price | $3.39 | $28.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $43.40 |
| AVG Volume (30 Days) | ★ 1.4M | 94.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $33.33 |
| Revenue Next Year | $33.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.02 | $7.76 |
| 52 Week High | $7.25 | $39.71 |
| Indicator | ASTL | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 29.96 | 46.78 |
| Support Level | $3.09 | $26.50 |
| Resistance Level | $4.77 | $30.66 |
| Average True Range (ATR) | 0.28 | 1.42 |
| MACD | -0.13 | -0.03 |
| Stochastic Oscillator | 0.69 | 27.35 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.